Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease

BACKGROUND: IMAgINE 1 assessed 52-week efficacy and safety of adalimumab in children with moderate to severe Crohn's disease. Long-term efficacy and safety of adalimumab for patients who entered the IMAgINE 2 extension are reported. METHODS: Patients who completed IMAgINE 1 could enroll in IMAg...

Descripción completa

Detalles Bibliográficos
Autores principales: Faubion, William A., Dubinsky, Marla, Ruemmele, Frank M., Escher, Johanna, Rosh, Joel, Hyams, Jeffrey S., Eichner, Samantha, Li, Yao, Reilly, Nattanan, Thakkar, Roopal B., Robinson, Anne M., Lazar, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Original Clinical Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319394/
https://www.ncbi.nlm.nih.gov/pubmed/28129288
http://dx.doi.org/10.1097/MIB.0000000000001021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319394/
https://www.ncbi.nlm.nih.gov/pubmed/28129288
http://dx.doi.org/10.1097/MIB.0000000000001021

Ejemplares similares